Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06745804 · ClinicalTrials.gov registry record · Phase 1
Study of 68Ga-R10602
A Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, sponsored by Radionetics Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 6
- Study locations
NCT06745804 is a Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer that is actively recruiting participants, run by Radionetics Oncology. The registered enrollment target is 36 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT06745804, a Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, is actively recruiting participants, sponsored by Radionetics Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 6
- Study locations
Study Summary
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Conditions Studied
Interventions
- DRUG 68Ga-R10602 injection
Study Locations (6)
California
- UCLA Department of Medicine - Hematology/Oncology - Los Angeles
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- University of Iowa - Iowa City
Michigan
- University of Michigan Medicine - Ann Arbor
Texas
- MD Anderson Cancer Center - Houston
Utah
- University of Utah, Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-12-10 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06745804
The ClinicalTrials.gov registry entry for NCT06745804 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radionetics Oncology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Locoregionally Recurrent Hormone-receptor Positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-R10602 injection is the first listed.
NCT06745804 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Indiana, Iowa.
Frequently Asked Questions
What is clinical trial NCT06745804 about?
NCT06745804 is a clinical study titled "Study of 68Ga-R10602". A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
What is the current status of trial NCT06745804?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-12-10. Estimated completion is 2026-07.
What conditions does trial NCT06745804 study?
This clinical trial studies the following conditions: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma.
What interventions are being tested in trial NCT06745804?
The interventions under investigation include: 68Ga-R10602 injection (DRUG).
Who is sponsoring clinical trial NCT06745804?
This trial is sponsored by Radionetics Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06745804 being conducted?
This trial has 6 study locations across California, Indiana, Iowa, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
All registered trials for this condition
Metastatic Hormone Receptor Positive Breast Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.